Genelux (United States)

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Derived from Wikipedia licensed CC-BY-SA.

Open Access statistics for Genelux (United States), United States, covering academic research published from 2003 to 2019. Read More.

Open Access Percentage

72%

Total
Publications

130

Total Open
Publications

Total
Citations

Open Access
Percentage

72%

Total
Publications

130

Total Open
Publications

Total
Citations

Wikipedia

Website

download

Breakdown

Publisher Open

10%

Both

48%

Other Platform Open

14%

Closed

28%

Percentage of Open Access over time

Publisher Open

Both

Other Platform Open

Closed

Volume of Open Access over time

Open

Closed

Publisher Open

OA Journal 55%

Hybrid 13%

No Guarantees 32%

Other Platform Open

Domain 96%

Institution 49%

Public 22%

Other Internet 5%

Preprint 0%

Other Platform Locations

Name	Platform Type	Publications
Europe PMC	Domain	79
PubMed Central	Domain	78
Würzburg University - Online Publication Service of Würzburg University	Institution	35
Semantic Scholar	Public	17
Cold Spring Harbor Laboratory - Cold Spring Harbor Laboratory Institutional Repository	Institution	4
Figshare	Public	2
DOI	Other Internet	2
whiterose.ac.uk OAI-PMH Repository	Institution	1
University of Twente - University of Twente Research Information	Institution	1
University of Granada - Institutional Repository of the University of Granada	Institution	1

1 / 2

Data updated 17 June 2024